Cassava Sciences(NASDAQ:SAVA) stock is falling Monday after the company shared an update on its Phase 3 trial for a treatment for Alzheimer's disease that has been widely followed by the market.

Martin Shkreli, a well-know figure in the pharmaceutical space, predicted the stock's crash Sunday night.

What Happened: Cassava Sciences reported that its Phase 3 topline results for the ReThink-ALZ study on Simufilam did not meet primary endpoints, sending shares significantly lower to start the trading week.

The company said it intends to present the data at an upcoming meeting, and Simufilam showed a favorable safety...